JCEM: Long-term safety of child growth hormone therapy

Growth hormone (GH) therapy is usually safe.
recently published a research paper in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, to assess the long-term safety of GH therapy in clinical practice.
researchers collected patient data from 676 clinics and conducted two multi-center longitudinal observational studies: the NordiNet International Results Study (Europe 2006-2016) and the ANSWER Program (2002-2016, United States).
who received GH treatment were divided into three risk groups based on diagnosis.
the intervention factor in the study was daily GH therapy.
the study's main outcome indicators were adverse drug reactions (ADRs), the occurrence of severe adverse events (SAEs) and severe ADRs (events/1000 patients-years), and their relationship to GH doses.
the study included 37,702 patients (68.4 per cent in the low-risk group, 27.5 per cent in the medium-risk group and 4.1 per cent in the high-risk group).
low-risk groups include children younger than gy childbearing age (SGA; 20.7%) and non-SGA children (e.g. GH deficiency; 79.3％）。
increases with the risk category until the average GH dose of the first adverse event (AE) decreases gradually.
in all groups, patients without AE received a higher average dose of GH than patients with AE.gt;1.
the ADR and SAE rates were significantly negatively associated with the GH dose in the low-risk groups (P=0.0029 and P=0.0003) and non-SGA subgroups (P=0.0022 and P=0.0015, respectively).
, the researchers did not find an increased risk of death or increased AE associated with GH doses in any risk group.